No black box warning on record for Nourianz

As of the latest FDA labeling reviewed, Nourianz (ISTRADEFYLLINE) does not carry a black box warning. Standard warnings and precautions still apply — see the full Nourianz medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Dyskinesia: Monitor patients for dyskinesia or exacerbation of existing dyskinesia ( 5.1 ). Hallucinations / Psychotic Behavior: Consider dosage reduction or stopping NOURIANZ if occurs ( 5.2 ). Impulse Control / Compulsive Behaviors: Consider dosage reduction or stopping NOURIANZ if occurs ( 5.3 ). 5.1 Dyskinesia NOURIANZ in combination with levodopa may cause dyskinesi

No black box warning on record for Nourianz

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Dyskinesia: Monitor patients for dyskinesia or exacerbation of existing dyskinesia ( 5.1 ). Hallucinations / Psychotic Behavior: Consider dosage reduction or stopping NOURIANZ if occurs ( 5.2 ). Impulse Control / Compulsive Behaviors: Consider dosage reduction or stopping NOURIANZ if occurs ( 5.3 ). 5.1 Dyskinesia NOURIANZ in combination with levodopa may cause dyskinesi

Nourianz Black Box Warning

No black box warning on record for Nourianz

Other warnings & precautions

Nourianz Black Box Warning

No black box warning on record for Nourianz

Other warnings & precautions